ARCA biopharma Total Liabilities

ARCA biopharma (ABIO) currently reports a total liabilities of $18M as of March 2026. That compares with $12M in the prior-year period — up 43.4% year over year. Use the charts on this page to explore ARCA biopharma's total liabilities history and peer comparisons.

ARCA biopharma's total liabilities increased from $12M to $18M — a 43.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ARCA biopharma reported $18M in total liabilities as of March 2026. That compares with $12M in the prior-year period — up 43.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ARCA biopharma, and consider following ABIO for alerts when major investors trade the stock.

ARCA biopharma is classified in the Healthcare sector. On total liabilities, it currently shows $18M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABIO with unrelated industries.